A phase II study of BAY 43–9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC)

Sorafenib (BAY 43-9006): Review of Clinical Development

“…Phase II studies of sorafenib in other tumor types have also been reported with promising activity seen in metastatic melanoma [36,37], prostate cancer [38,39], head and neck squamous cell carcinoma and nasopharyngeal cancer [40], breast cancer [41], pancreatic cancer [42], and non-small cell lung cancer [43].…”

The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents

“…Furthermore, gefitinib monotherapy has not produced significant clinical activity in patients with advanced refractory gastric cancer (148). However, pharmacodynamic data Improved objective response rates in second-line (186) Progression-free survival and overall survival benefit vs placebo (79,187) Minimal clinical activity in heavily pretreated patients (188) Minimal clinical activity in first-line (189) No clear clinical activity in pretreated patients however, increased disease stabilization suggests benefit (190) No significant clinical activity (98) Clinical activity as second-line treatment (92) Suggested increased activity in combination with gemcitabine as first-line treatment (97) Clinical activity in combination with platinum as second-line treatment (93) Increase in response rate, suggested survival advantage with the addition of cetuximab to cisplatin as first-line treatment (194) Clinical activity as first-line treatment (130) Survival advantage vs chemotherapy alone (gemcitabine) in first-line treatment (120) Minimal clinical activity (142) Minimal clinical activity (147) Minimal clinical activity (141) Clinical activity reported (139) Suggested increased activity combined with chemotherapy (docetaxel) as first-line treatment (146) The Role of VEGF and EGFR Inhibition…”